Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigations

68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer

Wolfgang P. Fendler, Dorothea F. Schmidt, Vera Wenter, Kolja M. Thierfelder, Christian Zach, Christian Stief, Peter Bartenstein, Thomas Kirchner, Franz J. Gildehaus, Christian Gratzke and Claudius Faber
Journal of Nuclear Medicine November 2016, 57 (11) 1720-1725; DOI: https://doi.org/10.2967/jnumed.116.172627
Wolfgang P. Fendler
1Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorothea F. Schmidt
1Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vera Wenter
1Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kolja M. Thierfelder
2Institute for Clinical Radiology, Ludwig-Maximilians-University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Zach
1Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Stief
3Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany
4Comprehensive Cancer Center, Ludwig-Maximilians-University of Munich, Munich, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bartenstein
1Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
4Comprehensive Cancer Center, Ludwig-Maximilians-University of Munich, Munich, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Kirchner
5Institute of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franz J. Gildehaus
1Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Gratzke
3Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany
4Comprehensive Cancer Center, Ludwig-Maximilians-University of Munich, Munich, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudius Faber
5Institute of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    SUVmax for histopathology-positive (HP+) or -negative (HP−) segments. (A) HP+ segments were further categorized by GS. Single values are given for each segment (n = 126); mean for each category is shown by bars. Results from Mann–Whitney test are given (*P < 0.05). (B) SUVmax was tested for accuracy in discrimination of HP+ from HP− segments. Receiver-operating-characteristic curve, area under curve (AUC), and optimal SUVmax cutoff as determined by Youden index are given.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    False-negative PET finding for acinar adenocarcinoma with partial neuroendocrine differentiation. 68Ga-PSMA PET/CT image (A), PSMA-stained slice (B), and hematoxylin-stained slice (C) for left mid (LM) and right mid (RM) segments are shown. PET SUVmax was 9.9 (true-positive) in LM segment. Tumor tissue with neuroendocrine differentiation and strong expression of neuroendocrine markers (chromogranin A, CD56; not shown) is delineated by black dots in RM segment. SUVmax was 5.5 (false-negative) in RM segment based on absence of PSMA expression in neuroendocrine prostate cancer lesions. STBPET3 (SUV ≥ 3.6) was 55% in LM segment (histopathology, 100%) and is delineated by red line.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Scatterplot for STB in PET-positive segments as determined by STBPET3 and STBHP. STBPET3 is based on (2 × blood SUV) + (2 × SD cutoff). Regression line (±SD) and results from Pearson test are given. n = 69.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    68Ga-PSMA PET/CT performance in 21 patients. Patients were grouped by optimal SUVmax cutoff as PET-positive or PET-negative. PET-positive patients were further parsed into those for whom PET and histopathology indicated highest STB in same glandular segment (maximum STB match) or in different segments (maximum STB mismatch).

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Accuracy of 68Ga-PSMA PET for Detection of Tumor Tissue per Segment

    PET resultHP+ (n = 100)HP− (n = 26)Accuracy
    PET+ (n = 69)672Positive predictive value, 97%
    PET− (n = 57)3324Negative predictive value, 42%
    Sensitivity, 67%Specificity, 92%Accuracy, 72%
    • HP = histopathology.

    • Six segments from 21 patients were analyzed.

    • View popup
    TABLE 2

    Correlation Between STBHP and STBPET1–6 in PET-Positive Segments (n = 69)

    ParameterSTBPET1STBPET2STBPET3STBPET4STBPET5STBPET6
    AlgorithmPERCISTLiver SUV(2 × blood SUV) + (2 × SD)(2 × blood SUV) + (4 × SD)Parotid SUV/2Parotid SUV/3
    Pearson ρ0.620.660.68‡0.650.400.47
    P<0.001*<0.001*<0.001*<0.001*0.001*<0.001*
    Mean Δ ± SD28% ± 22%22% ± 18%19% ± 15%†19% ± 17%33% ± 28%25% ± 23%
    • ↵* P < 0.05.

    • ↵† Highest ρ and lowest mean Δ ± SD.

    • View popup
    TABLE 3

    Accuracy of 68Ga-PSMA PET/CT for Detection of Histopathologically Proven (HP+) Invasion of Seminal Vesicles

    PET resultHP+ (n = 11)HP− (n = 10)Accuracy
    PET+ (n = 8)80Positive predictive value, 100%
    PET− (n = 13)310Negative predictive value, 77%
    Sensitivity, 73%Specificity, 100%Accuracy, 86%
    • HP = histopathology.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 57 (11)
Journal of Nuclear Medicine
Vol. 57, Issue 11
November 1, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer
Wolfgang P. Fendler, Dorothea F. Schmidt, Vera Wenter, Kolja M. Thierfelder, Christian Zach, Christian Stief, Peter Bartenstein, Thomas Kirchner, Franz J. Gildehaus, Christian Gratzke, Claudius Faber
Journal of Nuclear Medicine Nov 2016, 57 (11) 1720-1725; DOI: 10.2967/jnumed.116.172627

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer
Wolfgang P. Fendler, Dorothea F. Schmidt, Vera Wenter, Kolja M. Thierfelder, Christian Zach, Christian Stief, Peter Bartenstein, Thomas Kirchner, Franz J. Gildehaus, Christian Gratzke, Claudius Faber
Journal of Nuclear Medicine Nov 2016, 57 (11) 1720-1725; DOI: 10.2967/jnumed.116.172627
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • 68Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results
  • Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard
  • Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology
  • PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
  • Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
  • 68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters
  • Will GRPR Compete with PSMA as a Target in Prostate Cancer?
  • Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study
  • PSMA Ligands for PET Imaging of Prostate Cancer
  • 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
  • Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
  • Google Scholar

More in this TOC Section

  • Left Ventricular Strain from Myocardial Perfusion PET Imaging: Method Development and Comparison to 2-Dimensional Echocardiography
  • Prognostic Role of 68Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy
  • Radioimmunoscintigraphy and Pretreatment Dosimetry of 131I-Omburtamab for Planning Treatment of Leptomeningeal Disease
Show more Clinical Investigations

Similar Articles

Keywords

  • biopsy
  • PET
  • prostate cancer
  • PSMA
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire